Compression therapy market seen reaching $7.7 billion by 2035

Market Research Future says the global compression therapy market is on track to rise from $4.61 billion in 2025 to $7.70 billion by 2035, driven by aging populations, broader reimbursement and more care shifting into the home. North America leads today, while Asia-Pacific is expected to grow fastest over the forecast period.

Why it matters: - The compression therapy market is moving from a niche medical-device category into a larger home-care and reimbursement-driven business. - Market Research Future projects the global market will grow from $4.61 billion in 2025 to $7.70 billion by 2035, a 5.3% CAGR. - Demand is being lifted by chronic venous disease, lymphedema coverage expansion and more treatment moving out of hospitals.

What happened: - Market Research Future published a forecast showing the compression therapy market at $4.61 billion in 2025 and $4.84 billion in 2026. - The report said the market will reach $7.70 billion by 2035. - The forecast period runs from 2026 to 2035. - The report tied growth to aging populations and chronic venous insufficiency prevalence. - The report also pointed to Medicare lymphedema benefit expansion and home-based care adoption.

The details: - Roughly 25% of people in industrialized nations suffer from chronic venous illness. - Prevalence rises sharply after age 65. - The OECD expects people over 65 to make up 27% of the population across member states by 2035. - The annual cost of bandaging and clothing replacement for each diagnosed venous ulcer patient ranges from $480 to $720. - The Lymphedema Treatment Act took effect in January 2024 and expanded Medicare Part B reimbursement. - CMS allocated more than $1.6 billion over 10 years for lymphedema compression items under Part B. - U.S. home health agency episodes involving compression rose an estimated 18% between 2022 and 2025. - Germany’s statutory sickness funds cover two to four garment replacements per patient each year. - The European Medical Device Regulation forced a recertification cycle that removed weaker suppliers and favored larger manufacturers. - North America held 37.7% of 2025 revenue. - Asia-Pacific is expected to grow the fastest, at 6.1% CAGR.

Between the lines: - Reimbursement decisions appear to matter as much as clinical need in this market. - Coverage expansion can turn established therapies into faster-growing revenue streams without major changes to the underlying product category. - The shift toward home care favors lighter, patient-operable devices and vendors that can support direct-to-patient fulfillment. - The market is also consolidating around companies with regulatory scale, fitter networks and made-to-measure capabilities.

What's next: - Static compression therapy remains the largest technology segment, with a 63.0% share in 2025. - Dynamic compression therapy is the fastest-growing technology segment, at 6.1% CAGR. - Compression garments are the largest product segment, at $2.23 billion in 2025. - Compression pumps are the fastest-growing product segment, at 5.9% CAGR. - Venous leg ulcers are the largest application segment, with a 31.7% share in 2025. - Lymphedema treatment is the fastest-growing application segment, at 6.0% CAGR. - Hospitals remain the largest end user, with a 38.1% share in 2025. - Home care is the fastest-growing end-user segment, at 6.3% CAGR. - The report said connected pressure verification, emerging-market production, recovery and performance channels, data monetization and post-oncology lymphedema pathways could open new opportunities through 2035.

The bottom line: - Compression therapy is expected to keep growing steadily as aging demographics, reimbursement and home-based care broaden the addressable market.